...
首页> 外文期刊>The British journal of cancer >Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: A population pharmacokinetic study
【24h】

Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: A population pharmacokinetic study

机译:腹膜内清除是腹膜内围手术疗法后顺铂的潜在生物标志物:一项种群药代动力学研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Intraperitoneal (IP) perioperative chemotherapy with cisplatin is an interesting option in ovarian cancer treatment. A combination of cisplatin with IP epinephrine (already shown to improve IP and decrease systemic platinum (Pt) exposure) was evaluated using a population pharmacokinetic analysis.Methods: Data from 55 patients treated with cisplatin-based IP perioperative chemotherapy with (n=26) or without (n=29) epinephrine were analysed using NONMEM. Results: Epinephrine halves clearance between peritoneum and serum (IPCL) and increases the Pt central volume of distribution, IP exposure and penetration in tissue. IPCL has a better predictive value than any other parameter with respect to renal toxicity. Conclusion: This confirms that IPCL could be useful in assessing renal toxicity. As IPCL is also linked to tissue penetration and IP exposure, it may be proposed as biomarker. In addition to a Bayesian estimation, we propose a single-sample calculation-way to assess it. Prospective studies are needed to validate IPCL as a biomarker in this context.
机译:背景:顺铂腹膜内(IP)围手术疗法是卵巢癌治疗中有趣的选择。使用种群药代动力学分析评估了顺铂与IP肾上腺素的组合(已经证明可以改善IP和降低全身性铂(PT)暴露)。方法:55例接受顺铂基于IP的患者的数据,基于顺铂接受了基于Cisplatin的IP毛刺疗法,并使用(n = 26)(n = 26)或使用非MEM分析(n = 29)肾上腺素。结果:肾上腺素一半在腹膜和血清(IPCL)之间清除,并增加了PT的分布,IP暴露和组织中的渗透率。与肾脏毒性相比,IPCL具有比任何其他参数更好的预测值。结论:这证实IPCL可能有助于评估肾脏毒性。由于IPCL也与组织渗透和IP暴露有关,因此可以作为生物标志物。除了贝叶斯估计外,我们还提出了一个单样本计算方式来评估它。在这种情况下,需要进行前瞻性研究以验证IPCL为生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号